用逆转录病毒载体表达人粒细胞—巨噬细胞集落刺激因子

应用基因工程的方法,将含有巨细胞病毒（ＣＭＶ）启动子的基因片段和人粒细胞－茂噬细胞集落刺激因子（ｈＧＭ－ＧＳＦ）的ｃＤＮＡ,克隆进逆转录病毒载体Ｎ２Ａ,得到重组质粒Ｎ２ＱＡ／ＣＭＶ／ｈＧＭ－ＣＳＦ。经脂质体包装并转染包装细胞,通过Ｇ４１８药物筛选,得到抗生克隆。经ＰＣＲ和Ｓｏｕｔｈｅｒｎ ｂｌｏｔ检测证实,ＧＭ－ＣＳＦ基因已整合到该克隆细胞的染色体上,获得的逆转录病毒滴度达１０＾４ＣＦＵ／ｍｌ,克     

氧化诱导K_(562)细胞凋亡机制的初步探讨

以过氧化氢（Ｈ２Ｏ２）诱导人慢性髓细胞白血病（Ｋ５６２）细胞为凋亡模型,采用流式细胞仪（ｆｌｏｗｃｙｔｏｍｅｔｒｙ,ＦＣＭ）和激光共聚焦扫描显微镜（ｌａｓｅｒｃｏｎｆｏｃａｌｓｃａｎｎｉｎｇｍｉｃｒｏｓｃｏｐｙ,ＬＣＳＭ）研究细胞凋亡,形态观察出现核固缩,核碎裂及凋亡小体等典型凋亡特征．ＤＮＡ电泳图谱出现“Ｌａｄｄｅｒ”．ＦＣＭ检测在Ｇ０／Ｇ１峰前出现一低ＤＮＡ含量的凋亡峰．ＬＣＳＭ显示凋亡细胞ｃ－Ｆｏｓ．ｃ－Ｊｕｎ和ＮＦκＢ表达量均有不同程度的增加．该结果提示上述三种转录因子可能参与氧化诱导凋亡过程中基因的调控作用．     

用逆转录病毒载体表达人粒细胞－巨噬细胞集落刺激因子

应用基因工程的方法,将含有巨细胞病毒（ＣＭＶ）启动子的基因片段和人粒细胞－巨噬细胞集落刺激因子（ｈＧＭ－ＣＳＦ）的ｃＤＮＡ,克隆进逆转录病毒载体Ｎ２Ａ,得到重组质粒Ｎ２Ａ／ＣＭＶ／ｈＧＭ－ＣＳＦ．经脂质体包装并转染包装细胞,通过Ｇ４１８药物筛选,得到抗性克隆。经ＰＣＲ和Ｓｏｕｔｈｅｍｂｌｏｔ检测证实,ＧＭ－ＣＳＦ基因已整合到该克隆细胞的染色体上,获得的逆转录病毒滴度达１０￣４ＣＦＵ／ｍｌ,克隆细胞培养上清用ＴＦ－１细胞可检测到ＧＭ－ＣＳＦ活性。     

细胞松驰素B促微丝解聚对DNA合成的作用

利用微丝（ｍｉｃｒｏｆｉｌａｍｅｎｔ,ＭＦ）解聚药物细胞松驰素Ｂ（ｃｙｔｏｃｈａｌａｓｉｎＢ,ＣＢ）处理Ｇ_０期小鼠Ｃ_３Ｈ_（１０）Ｔ_（１／２）成纤维细胞,对Ｇ_０至Ｓ期ＤＮＡ合成,胸腺嘧啶核苷激酶（ｔｈｙｍｉｄｉｎｅｋｉｎａｓｅ,ＴＫ）活性、ＴＫ基因表达、钙调素（ｃａｌｍｏｄｕｌｉｎ,ＣａＭ）水平和一些细胞周期早期基因的表达进行了观察,Ｇ_０期细胞经３ｍｇ／ＬＣＢ处理２ｈ,促ＭＦ解聚增强了血清对Ｓ期细胞ＴＫ活性、ＴＫ基因表达和ＤＮＡ合成的刺激作用,并促进细胞提前进入Ｓ期．血清刺激Ｇ_０期细胞进入晚Ｇ_１期和Ｓ期时,ＣａＭ水平明显升高,而ＣＢ预处理则使ＣａＭ含量进一步增加,特别是ＣＢ处理促使Ｓ期ＣａＭ增加向核内转移．ＣＢ处理明显增强血清对ｃ－ｊｕｎ、ｃ－ｆｏｓ和ｃ－ｍｙｃ基因表达的刺激作用,而ＰＫＣ抑制剂Ｈ_７则抑制ＣＢ处理对这些基因转录的刺激作用,说明ＣＢ使Ｇ_０期细胞ＭＦ解聚刺激ｃ－ｊｕｎ、ｃ－ｆｏｓ和ｃ－ｍｙｃ的转录活性与ＰＫＣ的作用有关．结果表明Ｇ_０至Ｓ期早期ＭＦ的重组可促进细胞进入Ｓ期,增强ＤＮＡ合成．     

细胞松弛素B促微丝解聚对DNA合成的作用

利用微丝（ＭＦ）解聚药物细胞松弛素Ｂ（ＣＢ）处理Ｇ０期小鼠Ｃ３Ｈ１０Ｔ１／２成纤维细胞,对Ｇ０至Ｓ期ＤＮＡ合成,胸腺嘧啶核苷激酶（ＴＫ）活性、ＴＫ基因表达、钙调素（ＣａＭ）水平和一些细胞周期早期基因的表达进行了观察。Ｇ０期细胞经３ｍｇ／ＬＣＢ处理２ｈ,促ＭＦ解聚增强了血清对Ｓ期细胞ＴＫ活性、ＴＫ基因表达和ＤＮＡ合成的刺激作用,并促进细胞提前进入Ｓ期。血清刺激Ｇ０期细胞进入晚Ｇ１期和Ｓ期时,ＣａＭ     

低分子量硫酸葡聚糖对小鼠造血干细胞动员作用的研究

给小鼠静脉注射低分子量（＜１０￣４ｕ）硫酸葡聚糖（ＤＳ）１５ｍｇ／ｋｇ后外周血中白细胞、单个核细胞（ｍｏｎｏｎｕｃｌｅａｒｃｅｋ,ＭＮＣ）、ＣＦＵ－ＧＭ、ＢＦＵ－Ｅ和ＣＦＵ－Ｍｉｘ产率等指标出现时相性变化。给药后１ｈ开始升高,２ｈ达到高峰、分别为药前值的２．２、２．６、３．８、４．４和３．０倍,７ｈ时趋向正常。给药后２ｈ上述各类细胞在外周血中的含量随着ＤＳ的剂量增加而增加。白细胞、ＭＮＣ计数在ＤＳ１８０ｍｇ／ｋｇ时达到峰值,均为对照组的４倍。２４０ｍｇ／ｋ８时未见明显增加。不同剂量ＤＳ对各系祖细胞均有不同程度的动员作用,ＤＳ剂量１５－３０ｍｇ／ｋｇ效果最好,每升血中ＣＦＵ－ＧＭ、ＢＦＵ－Ｅ、ＣＦＵ－Ｍｉｘ的数量分别相当于对照组的５．０、１１．９和８．８倍。其峰值出现时间与白细胞、ＭＮＣ不同,表明ＤＳ对不同类型细胞的作用机制也不尽一致。经口给小鼠投以ＤＳ２４０和４８ｏｍｇ／ｋｇ后,未见外周血中白细胞、ＭＮＣ计数有显著性升高,提示对造血干细胞没有动员作用。     

几种扩血管多肽对bFGF促血管平滑肌细胞增殖作用的影响

目的和方法：研究肾上腺髓质素（Ａｄｍ）、降钙素基因相关肽（ＣＧＲＰ）及Ｃ－型心房利太（ＣＮＰ）对碱性成纤维细胞生长因子（ｂＦＧＦ）促血管平滑细胞（ＶＳＭＣ）增殖作用的影响及其机制。结果：孵育２４ｈ后,ｂＦＧＦ刺激ＶＳＭＣ增殖较对照组增加２．１倍（Ｐ〈０．０１）,细胞内蛋白磷酸化程度增加１．４倍（Ｐ〈０．０１）,ＰＫＣ及ＭＡＰＫ活性分别增加１．５和２．５倍（Ｐ〈０．０１０;Ａｄｍ．ＣＧＲＰｔ ＣＮＰ     

低氧对肺动脉内皮细胞PDGF—B链释放及平滑肌细胞生长的影响

应用蛋白ｄｏｔｂｌｏｔ技术检测了低氧内皮细胞条件培养液（ＨＥＣＣＭ）和常氧内皮细胞条件培养液（ＮＥＣＣＭ）内ＰＤＧＦ相对含量,并利用［３Ｈ］－ＴｄＲ掺入法和流式细胞术观察了ＨＥＣＣＭ和ＮＥＣＣＭ及加入特异ＰＤＧＦ抗体对肺动脉平滑肌细胞（ＰＡＳＭＣ）生长的影响。结果表明,ＨＥＣＣＭ中的ＰＤＧＦ含量明显高于ＮＥＣＣＭ;ＨＥＣＣＭ能明显增强ＰＡＳＭＣ内ＤＮＡ合成,促进ＰＡＳＭＣ从Ｇｏ／Ｇ１期进入Ｓ期;当预先加入ＰＤＧＦ－Ｂ链抗体时,则会明显地抑制ＨＥＣＣＭ对ＰＡＳＭＣ的ＤＮＡ合成,阻止ＰＡＳＭＣ从Ｇｏ／Ｇ１期进入Ｓ期。结果提示,低氧时ＰＡＳＭＣ增殖与肺动脉内皮细胞分泌释放ＰＤＧＦ增加有关     

钙调素对DNA合成的影响

利用钙调素ｃａｌｍｏｄｕｌｉｎ,ＣａＭ）拮抗剂─三氟拉嗪（ｔｒｉｆｌｕｏｐｅｒａｚｉｎｅ,ＴＦＰ）对Ｇ０期小鼠Ｃ３Ｈ１０Ｔ１／２成纤维细胞进入Ｓ期和ＤＮＡ合成进行了研究．Ｇ０期细胞进入Ｓ期时,大量钙调素进入细胞核,其水平为Ｇ０期的２倍。ＴＦＰ处理的细胞被阻抑在Ｇ１期,不仅使Ｓ期细胞群体下降,而且３Ｈ－ＴｄＲ掺入ＤＮＡ强度受到明显抑制．同时,ＴＦＰ处理的细胞胸腺嘧啶核苷激酶（ｔｈｙｍｉｄｉｎｅｋｉｎａｓｅ,ＴＫ）基因表达及ＴＫ活性亦明显下降,但不影响Ｓ期细胞核内的钙调素水平,结果表明钙调素功能之抑制不仅阻抑细胞从Ｇ１期至Ｓ期的进程,而且对细胞ＤＮＡ合成强度亦有抑制作用．     

基因重组白细胞介素3刺激胎肝巨核细胞祖细胞生长的特性

本文采用血浆凝块、甲基纤维素半固体和液体培养体系结合流式细胞仪巨核细胞ＤＮＡ双荧光分析,观察了４￣５个月胎肝和成人骨髓ＣＦＵ－ＭＫ在体外的增殖和分化特点。结果表明,无论以基因重组白细胞介素３或再障狗血清（Ｍｅｇ－ＣＳＡ）作为刺激因子,胎肝ＣＦＵ－ＭＫ集落均较大（大于５０个细胞／集落）,而成人骨髓ＣＦＵ－ＭＫ集落均较小（小于５０个细胞／集落）。在以ｒＩＬ３（２ｎｇ／ｍｌ）为刺激因子时,胎肝巨核细胞祖     

Characterization of cytostatic effector lymphocytes during the development of a syngeneic lymphosarcoma in C3H mice: use of monoclonal reagents to identify T-cell subsets

The development of the in vitro cytostatic capacity of splenic lymphocyte subpopulations from C3H mice carrying the syngeneic Gardner tumor was examined at different times after intramuscular tumor injection. Most mice died between 3 to 6 weeks after tumor injection, while some rejected their tumors or survived longer than 3 months. Cell separation procedures and monoclonal antibodies against T-cell subsets were used to identify the cells responsible in anti-tumor immunity. Cytostatic capacity against tumor cells developed in the T-cell enriched subpopulation of splenocytes 3 days after tumor injection and was partly abrogated by anti-Lyt-1. Effector function of Lyt-2+ T cells and B cells developed later and peaked at around 10 days after tumor injection. Another cell population with cytostatic capacity which was not blocked by anti-Lyt-1, anti-Lyt-2, or anti-Ly-5 was noted to develop early after tumor injection and lacked both T-cell and B-cell markers ("null"). This subpopulation was eluted with T cells from nylon wool columns and comprised up to 50% of the T-enriched fraction of splenocytes in later stages of tumor growth. An interesting characteristic of these "null" cells was susceptibility to T-cell suppression both in early and later stages of tumor growth except in regressor mice which lacked suppressor T cells. The cytostatic capacity of the "null" cells could be restored either by removal of Thy-1+ cells from the T-enriched fraction by panning, or the addition of anti-Thy-1 or F(ab')2 fragments of anti-Thy-1 to the lymphocyte-tumor reaction mixtures. Most mice examined after 10 days of tumor growth were immunosuppressed to varying degrees. Unseparated splenocytes from these mice were not cytostatic but removal of T cells allowed the B cells to exert their cytostatic capacity. A strong underlying B-cell cytostasis was shown to be present in long survivor mice even though their unseparated spleen cells were only weakly cytostatic. T cells did not play a role in the regression of tumors or long-term survival of tumor bearer mice. Splenocytes from regressor mice were strongly cytostatic, their anti-tumor activity residing in the "null" and B-cell populations.     

Tumor immunity in the mammary gland

Summary Mouse mammary tumor 410, which was derived from a spontaneously arising BALB/cf C3H mammary tumor, grows better in syngeneic BALB/c mice after injection into mammary fatpads than after injection into subcutaneous sites. This finding is consistent with the notion that the fatpad is an imunologically privileged site. However, no evidence that the mammary fatpad was immunologically privileged with respect to tumor transplantation antigens was found. Tumor cells were injected into mammary fatpads or SC. When the tumors became palpable they were surgically removed. One to three weeks later, the mice were challenged on the opposite side by injection of tumor cells either SC or into the mammary fatpad. The mice were immune after temporary growth of tumors either in the fatpad or SC. Regardless of the growth site of the immunizing tumor, the mice rejected the challenge tumor cells whether they were injected SC or into the fatpad.     

Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model

The immune system of vertebrates is able to detect bacterial DNA based on the presence of unmethylated CpG motifs. We examined the therapeutic potential of oligodeoxynucleotides with CpG motifs (CpG ODN) in a colon carcinoma model in BALB/c mice. Tumors were induced by s.c. injection of syngeneic C26 cells or Renca kidney cancer cells as a control. Injection of CpG ODN alone or in combination with irradiated tumor cells did not protect mice against subsequent tumor challenge. In contrast, weekly injections of CpG ODN into the margin of already established tumors resulted in regression of tumors and complete cure of mice. The injection site was critical, since injection of CpG ODN at distant sites was not effective. Mice with two bilateral C26 tumors rejected both tumors upon peritumoral injection of one tumor, indicating the development of a systemic immune response. The tumor specificity of the immune response was demonstrated in mice bearing a C26 tumor and a Renca tumor at the same time. Mice that rejected a tumor upon peritumoral CpG treatment remained tumor free and were protected against rechallenge with the same tumor cells, but not with the other tumor, demonstrating long term memory. Tumor-specific CD8 T cells as well as innate effector cells contributed to the antitumor activity of treatment. In conclusion, peritumoral CpG ODN monotherapy elicits a strong CD8 T cell response and innate effector mechanisms that seem to act in concert to overcome unresponsiveness of the immune system toward a growing tumor.     

人胃癌细胞株裸鼠皮下移植瘤模型的建立及其生物学特性

目的初步建立不同浓度下制备人胃癌细胞株BGC-823裸鼠皮下移植瘤模型,观察其生物学特性。方法培养人胃癌细胞系BGC-823细胞,并分别以四个浓度皮下注射于裸鼠腋下每只0.2 mL。根据BGC-823细胞注射浓度将40只裸鼠随机分为四组：组一5×107个活细胞/mL（n=10）;组二1×107个活细胞/mL（n=10）;组三1×106个活细胞/mL（n=10）;组四1×105个活细胞/mL（n=10）。观察各组裸鼠摄食、活动情况、精神状态、死亡率、成瘤时间、成瘤率、肿瘤生长情况,采用免疫组化法检测肿瘤微血管密度。结果各组裸鼠摄食、精神情况正常,无死亡现象。除组四1×105个活细胞/mL浓度组成瘤率为0%外,其余各组成瘤率均为100%,瘤体出现时间在3～7 d,肿瘤血管密度MVD平均为：（123.26±31.57）个/mm2。结论初步建立了人胃癌裸鼠皮下移植瘤模型及建立此细胞系模型的最低浓度。为胃癌的进一步研究奠定了基础。     

Immunotherapy of tumor-bearing mice utilizing virus help

Summary Utilizing vaccinia virus (VV), a tumor-specific immunotherapy model was established in which a growing tumor regressed. C3H/HeN mice were primed with VV after low dose irradiation to generate amplified VV-reactive T cell activities. Then 4 weeks later, the mice were inoculated i. d. with syngeneic MH134 hepatoma cells, and 6 days after the tumor cell inoculation, live VV was injected into the tumor mass 3 times at 2-day intervals. Of 10 mice which had received VV priming and subsequent VV injection into the tumor mass, 8 exhibited complete tumor regression. On the contrary, mice which had received only intratumoral VV injection without VV priming failed to exhibit appreciable tumor regression. Mice whose tumor had completely regressed following the VV immunotherapy were shown to have acquired systemic antitumor immunity, which was confirmed by a challenge with syngeneic tumor cells after immunotherapy. In vitro analysis of these immune mice revealed that potent tumor-specific antibody responses were preferentially induced, but with no detectable antitumor cytotoxic T lymphocyte (CTL) responses. Such a potent tumor-specific immunity was not observed in mice which had received intratumoral VV injection in the absence of VV priming. Thus, the results clearly indicate that tumor regression was accompanied by the concurrent generation of a potent tumor-specific immunity, suggesting that cellular cooperation between VV-reactive T cells and tumor-specific effector cells might be functioning in this VV immunotherapy protocol. Therefore, the present model provides an effective maneuver for tumor-specific immunotherapy. This system is, in principle, applicable to the human situation.     

Augmentation of delayed-type hypersensitivity and resistance against allogeneic or syngeneic methylcholanthrene-induced tumors in mice preimmunized with the tumor extracts

Delayed-type hypersensitivity (DTH) responses against methylcholanthrene-induced fibrosarcomas in C3H/He and BDF1 mice were developed in BDF1 mice by sc injection of the respective mitomycin C-treated tumor cells. The DTH responses to the allogeneic and the syngeneic tumor cells were accelerated and enhanced tumor-specifically by priming 7 days previously with KCl extracts of the respective tumors. The ability in the mice primed with the tumor extracts enhancing the DTH response against the tumor cells could be transferred to recipient mice by the spleen cells, but not by the T-cell-depleted spleen cells. Rejection of allogeneic tumor was accelerated under the development of accelerated and enhanced DTH response against the allogeneic tumor antigens. Moreover, resistance to syngeneic tumor growth increased significantly with the development of accelerated and enhanced DTH response against the syngeneic tumor antigens. Thus, the augmentation of DTH response by preimmunization with tumor extracts was accompanied by the increased resistance to tumor growth, suggesting that T cells involved in the augmentation of tumor-specific DTH response play some role in increasing the resistance to tumor growth.     

The use of immunologically competent cells from pig mesenteric lymph nodes to treat pulmonary tumors in mice

Summary Pulmonary tumors were produced in A strain mice by intravenous injection of 1×10⁶ A strain mammary carcinoma cells. The mice were killed on day 14, their lungs fixed in Bouin's fluid, and the number of tumors counted.The mesenteric lymph node chains of pigs were immunized by implantation of tissue into the mesentery. In all animals the middle segment of node chain was excised. The remaining segments of node proximal and distal to the resected segment were, in separate pigs, nonimmunized or immunized against mouse tumor, immunized against mouse tumor or mouse skin, or immunized against human tumor or mouse tumor. All segments of node chain were removed 7 days after immunization for preparation of cell suspensions.When tumor cells were combined in a ratio of 1 : 10 or 1 : 60 with mouse tumor-immune pig cells, there was a significant reduction in tumor formation compared to that in mice receiving tumor cells alone.Injection of mouse tumor-immune pig cells on day 7, to treat tumors inoculated on day 0, was ineffective. However, when the mice received, in addition, 200 rad thoracic irradiation on day 3, immune pig cells reduced the number of tumors compared to that in animals receiving irradiation alone, or irradiation and nonimmune pig cells.In further experiments, in order to increase the number of pig cells reaching the lungs, a splenectomy was performed on day 6, prior to intravenous injection of immune cells on day 7. A comparison was made of the antitumor effect of pig cells immunized against mouse tumor, mouse skin, or human tumor. Cells immunized against either mouse tissue were equally effective in reducing the number of tumors compared to the number in animals receiving tumor cells alone. However, cells immune to human tumor were ineffective.     

An intradermal assay for quantification and kinetics studies of tumor angiogenesis in mice.

A method is reported for the study of early phases of neovascularization in syngeneic murine tumors and human tumor xenografts in nude mice. Using this method, the effect of irradiation of tumor cells or tumor bed on tumor angiogenesis was studied. Tumor cells were injected intradermally in the abdominal skin flap, which was reopened at 2-day intervals to quantify newly formed blood vessels at the site of tumor cell injection. Both tumor cell injection and blood vessel counting were performed under a dissecting microscope. Using three syngeneic murine tumors and two clones of a human colonic adenocarcinoma, it was observed that new blood vessels started appearing within a few days after tumor cell injection and that this event preceded measurable tumor growth. The number of blood vessels increased exponentially for several days but then their further growth slowed. The extent of angiogenesis depended on the tumor type and the number of tumor cells injected. The exposure of the skin flap to ionizing radiation prior to tumor cell injection reduced neovascularization. We further observed that heavily irradiated tumor cells retained their ability to induce angiogenic response and that lymphoid cells (peritoneal exudate and spleen cells) could also elicit an angiogenic response, although it is weaker than the response elicited by tumor cells. Thus this method is suitable for quantification and kinetics of early phases of tumor angiogenesis in individual mice bearing transplants of syngeneic tumors or human tumor xenografts, and it can be useful for investigating various regulators of tumor angiogenesis.     

Specific T-cell factor production and lymphocytes in the direct surroundings of a subcutaneous allogeneic tumor.

Antigen-specific T-cell factors (TCF) play a role in the initiation of cellular immune responses. In allogeneic mouse-tumor models lymphocytes from the direct tumor surroundings of both euthymic and nude mice produce TCF. These lymphocytes produce TCF when collected already 1 day after subcutaneous (sc) injection of tumor cells. In contrast to euthymic mice, draining lymph nodes and spleen of nude mice did not contain TCF-producing lymphocytes at any stage after sc tumor cell injection. In sensitized euthymic mice TCF production by lymphocytes is significantly higher in the direct tumor surroundings than in draining lymph nodes or spleen. At 2 and 5 days after tumor cell injection, the mononuclear cell infiltrate of the tissue surrounding the tumor in euthymic mice showed low expression of Thy 1, CD3, TCR alpha beta, TCR gamma delta, CD4, CD8, and asialo GM1, whereas several lymphocytes and mast cells were positive for monoclonal antibody (mAb) 14-30 (directed against TCF). In both euthymic and nude mice, sc injected tumor cells showed apoptosis. In conclusion, the direct tumor surroundings are the first (and, for nude mice, the only) site of TCF production, sc injection of tumor cells attracts mAb 14-30-positive lymphocytes and renders mast cells positive for mAb 14-30.